Update: New Biomarkers Can Now be Used to Select Treatment for MBC
In our January 2023 issue, we discussed biomarkers for which there is not yet enough information to guide treatment decisions. Since then, clinical trials have...
Read More PAST ARTICLES
2024
2023
- What’s the Difference Between Targeted Therapy and Chemotherapy?
- Leaving a Legacy and Hope: Tissue Donation After Death
- The Latest Research on Inflammatory Breast Cancer
- How is ER Low Used in Clinical Trials?
- Shared Decision-Making: Collaborating with Your Doctors About Your Cancer Care
- Can I Participate in a MBC Clinical Trial if I Have Other Health Conditions?
- What are Clinical Practice Guidelines and How are They Developed?
- ASCO Experts Update Guidance for Sacituzumab Govitecan (Trodelvy®) for HR+, HER2- MBC
- What is Stable Disease and How is it Monitored?
- Biomarkers to Guide MBC Treatment Decisions: ESR1, PALB2, TROP2, HRD, ctDNA, and CTCs
2022
- Biomarkers to Guide MBC Treatment Decisions: dMMR/MSI-H, TMB, and NTRK Fusion
- Biomarkers to Guide MBC Treatment Decisions: PIK3CA, BRCA1/BRCA2, and PD-L1/PD-1
- Lobular Breast Cancer Metastasis: Highlighting the Researchers
- Breast Cancer Lung Metastasis: Highlighting the Experts
- Breast Cancer Liver Metastasis: Highlighting the Experts
- Breast Cancer Bone Metastasis: Highlighting the Experts
- Breast Cancer Brain Metastasis: Highlighting the Experts
- Why Do Some People Have an Exceptional Response When Being Treated for MBC?
- Why Does The Same Drug Work Differently In Different People?
- Male MBC Treatment And Clinical Trials
- MBC and NED
2021
- Treatment Strategies for Triple-Positive MBC
- Lobular Metastatic Breast Cancer
- Theragnostics
- Immunotherapy Resistance
- Lymphodepletion in Cancer Immunotherapy
- Local Therapies for Liver Mets
- Side Effects of Radiation Therapy for Brain Mets
- Screening for Breast Cancer Brain Metastases
- Circulating Tumor Cell Testing
- What is Next-Generation Sequencing?
2020
2019
SEARCH OUR SITE
for past articles or specific information.